Related Experiment Video
Updated: Feb 18, 2026
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
O6-methylguanine-DNA-methyltransferase immunostaining intensity in glioblastoma
Daniel Jiménez1, José Manuel Matamala2, Alessandra Chiti3
1Laboratory of Biomedical Sciences, Department of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile; Neurology Service, Hospital del Salvador, Santiago, Chile.
Abstract:
Immunohistochemistry (IHC) for O6-methylguanine-DNA-methyltransferase (MGMT) has shown heterogeneous results. Cell staining intensity has not been included as a quantifiable variable in IHC analyses. We performed MGMT IHC in 29 patients diagnosed as glioblastoma classifying cells into three categories based on nuclear staining intensity compared with adjacent endothelium. The median proportions of strong-moderate, weak and no staining cells were 10%, 16% and 71%, respectively. The proportion of positive cases for MGMT expression varies from 38% to 52% depending on the classification of weakly stained cells. This letter challenges previous studies that have not included intensity as a variable for IHC analysis.
Insights
O6-methylguanine-DNA-methyltransferase (MGMT) immunohistochemistry (IHC) results vary. Quantifying cell staining intensity in MGMT IHC is crucial for accurate glioblastoma analysis, as current methods lack this variable.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Immunohistochemistry (IHC) for O6-methylguanine-DNA-methyltransferase (MGMT) is used in glioblastoma research.
- Previous IHC analyses have not consistently quantified cell staining intensity.
Discussion:
- This study introduces a method to classify MGMT IHC staining intensity into three categories: strong-moderate, weak, and no staining.
- The analysis revealed median proportions of 10% strong-moderate, 16% weak, and 71% no staining cells.
- The classification of weakly stained cells impacts the proportion of positive MGMT expression cases, ranging from 38% to 52%.
Key Insights:
- Cell staining intensity is a critical, yet often overlooked, variable in MGMT IHC analysis for glioblastoma.
- Inconsistent classification of weak staining can lead to significant variations in reported MGMT expression rates.
- Accurate MGMT assessment is vital for treatment decisions in glioblastoma.
Outlook:
- Future glioblastoma research should incorporate quantitative staining intensity in MGMT IHC protocols.
- Standardizing MGMT IHC analysis by including intensity will improve diagnostic accuracy and therapeutic stratification.
- Further studies are needed to validate the clinical significance of quantified MGMT staining intensity in glioblastoma.
